Nakamura et al. described how ovarian cancer-derived exosomes reprogram PMCs with a mesenchymal phenotype (i.e., mesothelial–mesenchymal transition (MMT)) by transferring CD44 and subsequently promote ovarian cancer cell invasion and metastasis [12]. Here, CD44 is linked to ovarian cancer.